Publications Internationales (*en tant que collaborateur(s) à des études multicentriques)

1. N. Veziris, C. Bernard, L. Guglielmetti, D. Le Dû, D. Marigot-Outtandy, M. Jaspard, E. Caumes, I. Lerat, C. Rioux, Y. Yazdanpanah, A. Tiotiu, N. Lemaitre, F. Brossier, V. Jarlier, J. Robert, W. Sougakoff, A. Aubry. 2016. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance : lessons not to repeat past errors. European Respiratory Journal : (in press).
2. Bernard C, Aubry A, Chauffour A, Brossier F, Robert J, Veziris N. 2016. In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence : a complex phenomenon poorly detected by current diagnostic tests. J Antimicrob Chemother 71:3465–3472.
3. Brossier F, Boudinet M, Jarlier V, Petrella S, Sougakoff W. 2016. Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb) 100:15–24.
4. Brossier F, Cambau E, Tessier E, Jarlier V, Sougakoff W. 2016. The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:144–145.
5. Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, Aubry A, French National Reference Center for Mycobacteria (Members of the French National Reference Center for Mycobacteria : Christine Bernard, Emmanuelle Cambau, Vincent Jarlier, Faiza Mougari, Laurent Raskine, Jérôme Robert). 2016. Performance of the New V2.0 of the GenoType MTBDRsl Test for the Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. J Clin Microbiol 54:1573–1580.
6. Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N, Sougakoff W, CNR-MyRMA. 2016. Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother Nov 28:pii : AAC.01299-16.
7. Chauffour A, Robert J, Veziris N, Aubry A, Jarlier V. 2016. Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS Negl Trop Dis 10:e0005066.
8. Guglielmetti L, Le Dû D, Veziris N, Caumes E, Marigot-Outtandy D, Yazdanpanah Y, Robert J, Fréchet-Jachym M, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort. 2016. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis ? Eur Respir J 48:582–585.
9. Pantel A, Petrella S, Veziris N, Matrat S, Bouige A, Ferrand H, Sougakoff W, Mayer C, Aubry A. 2016. Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. J Antimicrob Chemother 71:2428–2431.
10. Chazel M, Marchandin H, Keck N, Terru D, Carrière C, Ponsoda M, Jacomo V, Panteix G, Bouzinbi N, Bañuls A-L, Choisy M, Solassol J, Aubry A, Godreuil S. 2016. Evaluation of the SLOMYCO Sensititre(®) panel for testing the antimicrobial susceptibility of Mycobacterium marinum isolates. Ann Clin Microbiol Antimicrob 15:doi : 10.1186/s12941-016-0145-1.
11. Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. 2016. Rifabutin : where do we stand in 2016 ? J Antimicrob Chemother 71:1759–1771.
12. Fox GJ, Benedetti A, Mitnick CD, Pai M, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2016. Propensity Score-Based Approaches to Confounding by Indication in Individual Patient Data Meta-Analysis : Non-Standardized Treatment for Multidrug Resistant Tuberculosis. PLoS ONE 11:e0151724.
13. Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang C-Y, Keshavjee S, Koh W-J, Shiraishi Y, Viiklepp P, Yim J-J, Pasvol G, Robert J, Shim TS, Shin SS, Menzies D, Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. 2016. Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis : An Individual Patient Data Metaanalysis. Clin Infect Dis 62:887–895.
14. Henry B, Revest M, Dournon N, Epelboin L, Mellon G, Bellaud G, Mordant P, Le Dû D, Véziris N, Bernard C, Morel S, Jauréguiberry S, Michelet C, Bricaire F, Tattevin P, Caumes É. 2016. Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014. Emerging Infect Dis 22:518–521.
15. Lachâtre M, Rioux C, Dû DL, Fréchet-Jachym M, Veziris N, Bouvet E, Yazdanpanah Y. 2016. Bedaquiline plus delamanid for XDR tuberculosis. Lancet Infect Dis 16:294.
16. Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F, European MDR-TB database collaboration *. 2016. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe. Am J Respir Crit Care Med 194:1029–1031.
17. Lortholary O, Roussillon C, Boucherie C, Padoin C, Chaix M-L, Breton G, Rami A, Veziris N, Patey O, Caumes E, May T, Molina J-M, Robert J, Tod M, Fagard C, Chêne G, ANRS 129 BKVIR Trial Group. 2016. Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis : the ANRS 129 BKVIR trial. J Antimicrob Chemother 71:783–793.*
18. Mougari F, Amarsy R, Veziris N, Bastian S, Brossier F, Berçot B, Raskine L, Cambau E. 2016. Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. J Antimicrob Chemother 71:2208–12.
19. Mougari F, Bouziane F, Crockett F, Rachid NR, Chau F, Veziris N, Sapriel G, Raskine L, Cambau E. 2016. Selection of resistance to clarithromycin with regard to the subspecies in Mycobacterium abscessus. Antimicrob 82 Agents Chemother Oct 31:pii : AAC.00943-16.
20. Mougari F, Guglielmetti L, Raskine L, Sermet-Gaudelus I, Veziris N, Cambau E. 2016. Infections caused by Mycobacterium abscessus : epidemiology, diagnostic tools and treatment. Expert Rev Anti Infect Ther 14:1139– 1154.
21. Petrella, S., A. Aubry, G. Janvier, E.P. Coutant, A. Cartier, T.H Dao, F.J. Bonhomme, L. Motreff, C. Pissis, C. Bizet, D. Clermont, E. Begaud, P. Retailleau, H. Munier-Lehmann, E. Capton, C. Mayer, Y.L. Janin. 2016. Synthesis and evaluation of original bioisosteres of bacterial type IIA topoisomerases inhibitors. Can J Chem 94(3) : 240-250
22. Mougari F, Bouziane F, Crockett F, Nessar R, Chau F, Veziris N, Sapriel G, Raskine L, Cambau E. Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies. Antimicrob Agents Chemother. 2016 Dec 27 ;61(1).
23. Raharolahy O, Ramarozatovo LS, Ranaivo IM, Sendrasoa FA, Andrianarison M, Andrianarivelo MR, Cambau E, Rabenja FR. A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. Case Rep Infect Dis. 2016 ;
24. Mieras L, Anthony R, van Brakel W, Bratschi MW, van den Broek J, Cambau E, Cavaliero A, Kasang C, Perera G, Reichman L, Richardus JH, Saunderson P, Steinmann P, Yew WW. Negligible risk of inducing resistance in Mycobacterium tuberculosis with single-dose rifampicin as post-exposure prophylaxis for leprosy. Infect Dis Poverty. 2016 Jun 8 ;5(1):46

Publications nationales

1. Guglielmetti L., Robert J. 2015. Bédaquiline : de l’in vitro aux essais cliniques d’un nouvel antituberculeux. J Anti-infectieux 17. Hervé C, Bergot E, Veziris N, Blanc F-X. 2015. [Tuberculosis in 2015 : From diagnosis to the detection of multiresistant cases]. Rev Mal Respir 32:784–790.
2. Reibel F, Cambau E, Aubry A. 2015. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect 45:383–393.
3. Reibel F, Cambau E, Aubry A. 2015. Les anti-lépreux. Journal des anti-infectieux.
4. Robert J. 2015. Focus. Résistance aux antituberculeux en France en 2013. Brossier F, Aubry A. 2016. Résistance de Mycobacterium tuberculosis aux antituberculeux. Feuillets de biologie 328:17–25.
5. Lafeuille E, Veziris N, Sougakoff W, Roure F, Le Dû D, Dournon N, Caumes E, Jarlier V, Aubry A, Robert J, Bernard C. 2016. XDR-tuberculosis in France : Community transmission due to non-compliance with isolation precautions. Med Mal Infect 46:52–55.
6. Maitre T, Aubry A, Jarlier V, Robert J, Veziris N, CNR-MyRMA. 2016. Multidrug and extensively drug-resistant tuberculosis. Med Mal Infect Sep 13:pii : S0399-077X(16)30143-3.

Chapitres d’ouvrage

1. Biosafety in the laboratory diagnosis of tuberculosis, Maryse Fauville-Dufaux, Vincent Jarlier, Dick van Soolingen, Sven Hoffner in « Tuberculosis handbook » (ECDC, 1st edition 2011 ; 2nd édition 2016).
2. First- and second-line drug susceptibility testing for Mycobacterium tuberculosis complex Emmanuelle Cambau, Sabine Rüsch-Gerdes in « Tuberculosis handbook » (ECDC, 1st edition 2011 ; 2nd édition 2016).

2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005 / 2004 / 2003